
Brent Saunders [Getty Photos]
AbbVie seals $63B deal to buy a troubled Allergan — spelling out $1B in R&D cuts
Brent Saunders has found his way out of the current fix he’s in at Allergan $AGN. He’s selling the company to AbbVie for $63 billion in the latest example of the hot M&A market in biopharma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.